HealthCare Royalty, Supernus in Orenitram royalty deal

HealthCare Royalty Partners paid Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) $30 million in cash for an undisclosed portion of milestones and royalties Supernus is eligible to receive from United Therapeutics Corp. (NASDAQ:UTHR) for Orenitram treprostinil. The pulmonary arterial hypertension drug -- an oral, sustained-release formulation of treprostinil, a synthetic long-acting stable prostacyclin analog -- uses Supernus' EnSoTrol osmotic oral delivery technology. United Therapeutics launched Orenitram in the U.S. in April. Supernus is eligible for undisclosed milestones plus royalties. ...